Health care stocks were falling Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down about 1.1%.
The iShares Biotechnology ETF (IBB) fell 1.4%.
In corporate news, 23andMe's (ME) customers were asked by New York Attorney General Letitia James to take action for protection of their data as the company goes through bankruptcy, the state prosecutor's office said in a consumer alert Tuesday. 23andMe shares were falling past 13%.
Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. Merck shares were down 4.1%.
Alumis (ALMS) shares rose past 7% after the company and Kaken Pharmaceutical said they signed a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001 for dermatology indications in Japan, with an option to expand the license to include rheumatological and gastrointestinal diseases.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。